Canadian authorities grant product approval for Intercell's Vaccine to prevent Japanese Encephalitis
Intercell AG announced that the Health Canada granted product approval for IXIARO®, the company's vaccine to prevent Japanese encephalitis (JE). According to the company, this decision of the Canadian authorities represents another important milestone for the product's global reach. Intercell's vaccine to prevent Japanese Encephalitis has already been successfully approved and launched in the USA, Europe and Australia.
"We are very pleased that IXIARO is now also approved by the Canadian authorities. This reflects another step in growing our IXIARO business by supplying this important product to travelers", states Gerd Zettlmeissl, Chief Executive Officer of Intercell.
Intercell's Japanese Encephalitis vaccine will be available for the Canadian market by the end of the year and will be distributed and marketed to travel clinics by Novartis Pharmaceuticals Canada Inc. and to the military personnel by Intercell.
IXIARO is a purified, inactivated product for active immunization against infection by the Japanese Encephalitis Virus. IXIARO is manufactured at Intercell's proprietary manufacturing facility in Scotland and is prepared using tissue culture rather than live organisms.
Other news from the department research and development
